Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-Oxo‑4,5‑dihydro‑1,2,5‑thiadiazole‑3-carboxylic acid is a small molecule belonging to the thiadiazole family. It features a five-membered heterocyclic ring containing two nitrogen atoms and one sulfur atom. The compound has been studied primarily as an experimental inhibitor of L-lactate dehydrogenase (LDH), particularly the A and B chains (LDHA and LDHB). Its structure includes both carboxylic acid and oxo functional groups. While it has shown potential for biochemical applications—especially as an LDH inhibitor—there are no approved medical indications or clinical trials reported for this compound. It is mainly used in research settings to probe metabolic enzyme function or as a synthetic intermediate in medicinal chemistry[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-oxo-4,5-dihydro-1,2,5-thiadiazole-3-carboxylic acid.